Product Code：C140002A
English Name：Cyclobenzaprine Impurity 2(Hydrochloride)
English Alias：3-(5H-dibenzo[a,d][7]annulen-5-ylidene)-N-methylpropan-1-amine hydrochloride
CAS No.：438-59-5
Molecular Formula：C₁₉H₁₉N·HCl
Molecular Weight：261.36 (free base) + 36.46 (hydrochloride) = 297.82
High-Purity Reference Standard：Confirmed by HPLC (≥99.0%), NMR (1H, 13C), HRMS, and elemental analysis, suitable for Cyclobenzaprine impurity analysis and quality control.
Stability Assurance：Stable for 36 months at -20℃ under light-protected, sealed storage; degradation rate <0.3% in methanol-water system within 6 months.
Quality Control Testing：Used for UPLC-MS/MS detection of Impurity 2 hydrochloride in Cyclobenzaprine API and formulations, controlling content to meet ICH Q3A standards (single impurity limit ≤0.1%).
Process Optimization Research：Monitors Impurity 2 formation during Cyclobenzaprine synthesis, reducing generation by >40% by adjusting condensation temperature (e.g., 60-70℃) and reaction time.
Method Validation：Serves as a standard for developing impurity detection methods, verifying UPLC resolution (≥3.0) and LOD (0.01 ng/mL).
Cyclobenzaprine, a skeletal muscle relaxant, is used to relieve muscle spasms. Impurity 2 hydrochloride, as a process-related impurity of Cyclobenzaprine, may originate from condensation side reactions between dibenzocycloheptene rings and amine compounds. Its methylene and hydrochloride groups may affect drug stability and pH. With stricter requirements from global regulatory agencies for muscle relaxant impurities, studying Impurity 2 is crucial for ensuring drug quality.
Detection Technology：UPLC-MS/MS with C18 column (1.7μm) and 0.1% formic acid-acetonitrile gradient elution achieves separation within 5 minutes, with LOD of 0.005 ng/mL for trace impurity analysis.
Formation Mechanism：Formed by condensation of dibenzocycloheptenone with N-methylpropylamine under acidic conditions (e.g., acetic acid catalysis) to give the free base, followed by salification with hydrochloric acid; optimizing catalyst dosage and reaction pH inhibits side reactions.
Safety Evaluation：In vitro cytotoxicity shows IC₅₀ of 189.6 μM against C2C12 muscle cells (Cyclobenzaprine IC₅₀=12.3 μM), with lower toxicity than the main drug but requiring strict content control. Long-term stability testing is ongoing to monitor degradation under different humidity, light, and temperature conditions.
WhatsAPP: +86 17320513646
China
